Sep. 10 at 3:18 PM
$AMRN
Background:
If
$TRML (with 25M shares) with products at 50% of Phase 2. This means at least about > 5~6 years from today for the trial to end with significant results, assuming no major safety concern. With so many unknown factors,
$NVS bought it with a premium yesterday..
Question:
With proven and a SLOW revenue generating (for the time being) product with Zero debt, COH ~
$300M, with Class IIA, Level B approval in EU. Although
$AMRN’s unknown factors like LR EtEPA and EU’s turnaround are sure for success but exact time is unknown.
Court case, NRDL, etc., - Big Pharma can take the same risk as of
$TRML, just saying
Only two reasons, I can think of why no such offers for
$AMRN (with 21M shares)
1) Either AD is demanding too much, may be >
$5~6B
Or
2) Big Pharma is offering too low, may be <
$2B
But as long, I am absolutely fine with
$2-3B BO
